Cargando…
NDEL1-PDGFRB fusion gene in a myeloid malignancy with eosinophilia associated with resistance to tyrosine kinase inhibitors
Autores principales: | Byrgazov, K, Kastner, R, Gorna, M, Hoermann, G, Koenig, M, Lucini, C B, Ulreich, R, Benesch, M, Strenger, V, Lackner, H, Schwinger, W, Sovinz, P, Haas, O A, van den Heuvel-Eibrink, M, Niemeyer, C M, Hantschel, O, Valent, P, Superti-Furga, G, Urban, C, Dworzak, M N, Lion, T |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5220134/ https://www.ncbi.nlm.nih.gov/pubmed/27573554 http://dx.doi.org/10.1038/leu.2016.250 |
Ejemplares similares
-
Transposon-mediated generation of BCR-ABL1-expressing transgenic cell lines for unbiased sensitivity testing of tyrosine kinase inhibitors
por: Byrgazov, Konstantin, et al.
Publicado: (2016) -
Cell biology: A key driver of therapeutic innovation
por: Hantschel, Oliver, et al.
Publicado: (2012) -
Detection of a PDGFRB fusion in refractory CMML without eosinophilia: A case for broad spectrum tumor profiling
por: Bell, Gillian C., et al.
Publicado: (2015) -
The Phenotype and Treatment of WIP Deficiency: Literature Synopsis and Review of a Patient With Pre-transplant Serial Donor Lymphocyte Infusions to Eliminate CMV
por: Schwinger, Wolfgang, et al.
Publicado: (2018) -
Targeting allosteric regulatory modules in oncoproteins: “Drugging the Undruggable”
por: Hantschel, Oliver, et al.
Publicado: (2011)